ALINORM 03/26/1 - codex - BSN
ALINORM 03/26/1 - codex - BSN
ALINORM 03/26/1 - codex - BSN
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
20 REP12/CAC<br />
113. The result of the secret ballot on Vote 2 was:<br />
Ballots papers deposited: 143<br />
Defective ballots: 0<br />
Abstentions: 7<br />
Votes cast: 136<br />
Majority required: 69<br />
Votes in favour: 69<br />
Votes against: 67<br />
Result: Proposal adopted; the Commission adopted the MRLs for ractopamine<br />
in cattle and pig tissues, i.e., muscle, liver, kidney and fat.<br />
114. The Delegation of China expressed their disappointment that the Commission did not resolve the issue<br />
by consensus. They reiterated their position against the adoption of the MRLs for ractopamine and expressed<br />
their reservation.<br />
115. The Delegation of Norway strongly opposed the adoption of the draft MRLs, as they still had human<br />
health concerns and because of the non-therapeutic use of ractopamine. The Delegation was concerned<br />
because the draft MRLs had been pushed forward when many members had asked for a consensus-based<br />
decision and the MRLs had been adopted despite a clear lack of consensus. They noted that without a global<br />
agreement the MRLs would not be applicable worldwide.<br />
116. The Delegation of the European Union stated that it was strongly opposed to the adoption of the MRLs<br />
for ractopamine in pigs and cattle as there were outstanding concerns regarding its safety assessment. The<br />
European Union's risk assessment body, the European Food Safety Authority, concluded that there is<br />
insufficient data upon which to make a proposal for MRLs for ractopamine and that possible risks to human<br />
health had not been sufficiently ruled out. As ractopamine is solely used for the purpose of growth promotion,<br />
the European Union could not support an international standard that endorsed, or worse still, encouraged its<br />
use.<br />
117. The European Union, therefore, recorded its strong opposition to the adoption of the MRLs for<br />
ractopamine by the Commission. The Delegation also underlined that, given its outstanding safety concerns,<br />
the European Union's current legislation would remain in place. The Delegation was also of the view that the<br />
Commission should take time to reflect upon what to do about standards held at Step 8. There had been a<br />
number of attempts to seriously consider what to do in these cases, and yet, for a variety of reasons, these<br />
attempts had been thwarted and no real progress had been possible. The Delegation emphasised that it was in<br />
the best interest of the Commission to seriously reflect on this matter.<br />
118. The European Union stressed that Codex, as a consensus-based organisation had not been well served<br />
by what had happened at this session of the Commission. The membership of Codex, had spoken out, loud<br />
and clear on various occasions, expressing their clear preference for matters to be decided in Codex on the<br />
basis of consensus. By conducting a vote at this session, this preference had been blatantly ignored. The<br />
European Union deplored not only the fact that an international standard had been set for ractopamine but<br />
also deplored, in the strongest of terms, the manner in which this conclusion was reached. For the above<br />
reason, the European Union recorded their strong opposition to the adoption of the MRLs for ractopamine.<br />
119. The Delegation of the United States of America stated that they were pleased with the adoption of the<br />
MRLs for ractopamine, but they took no pleasure in the fact that this had been a difficult decision. The<br />
Delegation thanked the Chairpersons of the Commission and the CCRVDF for all efforts made over the years<br />
to try to achieve consensus and to use all the tools in the Procedural Manual to find a way forward. The<br />
Delegation expressed the wish that adopting standards in Codex through a vote should remain a rare<br />
exception to the general rule of consensus. They looked forward to working with members to ensure that<br />
Codex remains willing and able to make science-based and timely decisions on food safety.<br />
120. The following delegations expressed their reservation to the adoption of the MRLs for ractopamine<br />
and made the following comments:<br />
- Kenya: was of the view that not all safety concerns had been addressed and that with such sustained<br />
opposition no international standard should be set.